A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients
- 28 January 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 23 (3), 357-368
- https://doi.org/10.1097/qad.0b013e32831f9148
Abstract
Objective: Whether therapeutic drug monitoring of protease inhibitors improves outcomes in HIV-infected patients is controversial. We evaluated this strategy in a randomized, open-label clinical trial, using a normalized inhibitory quotient (NIQ), which incorporates drug exposure and viral drug resistance. NIQs ≤ 1 may predict poor outcome and identify patients who could benefit from dose escalation. Design/methods: Eligible patients had a viral load ≥1000 copies/ml on a failing regimen, and began a new protease inhibitor containing regimen at entry. All FDA-approved protease inhibitors available during the study recruitment (June 2002–May 2006) were allowed. One hundred and eighty-three participants with NIQ ≤ 1, on the basis of their week 2 protease inhibitor trough concentration and pre-entry drug resistance test, were randomized at week 4 to standard of care (SOC) or protease inhibitor dose escalation (TDM). The primary endpoint was change in log10 plasma HIV-1 RNA concentration from randomization to 20 weeks later. Results: Ninety-one patients were randomized to SOC and 92 to TDM. NIQs increased more in the TDM arm compared to SOC (+69 versus +25%, P = 0.01). Despite this, TDM and SOC arms showed no difference in outcome (+0.09 versus +0.02 log10, P = 0.17). In retrospective subgroup analyses, patients with less HIV resistance to their protease inhibitors benefited from TDM (P = 0.002), as did black and Hispanic patients (P = 0.035 and 0.05, respectively). Differences between black and white patients persisted when accounting for protease inhibitor susceptibility. Conclusions: There was no overall benefit of TDM. In post hoc subgroup analyses, TDM appeared beneficial in black and Hispanic patients, and in patients whose virus retained some susceptibility to the protease inhibitors in their regimen.This publication has 36 references indexed in Scilit:
- Maraviroc for Previously Treated Patients with R5 HIV-1 InfectionThe New England Journal of Medicine, 2008
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionThe New England Journal of Medicine, 2008
- Raltegravir with Optimized Background Therapy for Resistant HIV-1 InfectionThe New England Journal of Medicine, 2008
- Predictive Values of the Human Immunodeficiency Virus Phenotype and Genotype and of Amprenavir and Lopinavir Inhibitory Quotients in Heavily Pretreated Patients on a Ritonavir-Boosted Dual-Protease-Inhibitor RegimenAntimicrobial Agents and Chemotherapy, 2008
- Genotypic Susceptibility Scores and HIV Type 1 RNA Responses in Treatment-Experienced Subjects with HIV Type 1 InfectionAIDS Research and Human Retroviruses, 2008
- The Design and Implementation of A5146, a Prospective Trial Assessing the Utility of Therapeutic Drug Monitoring Using an Inhibitory Quotient in Antiretroviral-Experienced HIV-Infected PatientsHIV Research & Clinical Practice, 2008
- Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus InfectionAntimicrobial Agents and Chemotherapy, 2006
- Pharmacokinetic and Safety Evaluation of High-Dose Combinations of Fosamprenavir and RitonavirAntimicrobial Agents and Chemotherapy, 2006
- GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy*HIV Medicine, 2004
- Weighted Phenotypic Susceptibility Scores Are Predictive of the HIV‐1 RNA Response in Protease Inhibitor–Experienced HIV‐1–Infected SubjectsThe Journal of Infectious Diseases, 2004